Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
74.80
+1.12 (1.52%)
At close: May 12, 2025, 4:00 PM
74.94
+0.14 (0.18%)
After-hours: May 12, 2025, 5:12 PM EDT
Edwards Lifesciences Employees
Edwards Lifesciences had 15,800 employees as of December 31, 2024. The number of employees decreased by 4,000 or -20.20% compared to the previous year.
Employees
15,800
Change (1Y)
-4,000
Growth (1Y)
-20.20%
Revenue / Employee
$349,513
Profits / Employee
$264,601
Market Cap
43.88B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,800 | -4,000 | -20.20% |
Dec 31, 2023 | 19,800 | 2,500 | 14.45% |
Dec 31, 2022 | 17,300 | 1,600 | 10.19% |
Dec 31, 2021 | 15,700 | 800 | 5.37% |
Dec 31, 2020 | 14,900 | 1,000 | 7.19% |
Dec 31, 2019 | 13,900 | 1,100 | 8.59% |
Dec 31, 2018 | 12,800 | 600 | 4.92% |
Dec 31, 2017 | 12,200 | 1,100 | 9.91% |
Dec 31, 2016 | 11,100 | 1,300 | 13.27% |
Dec 31, 2015 | 9,800 | 700 | 7.69% |
Dec 31, 2014 | 9,100 | 500 | 5.81% |
Dec 31, 2013 | 8,600 | 400 | 4.88% |
Dec 31, 2012 | 8,200 | 400 | 5.13% |
Dec 31, 2011 | 7,800 | 800 | 11.43% |
Dec 31, 2010 | 7,000 | 600 | 9.38% |
Dec 31, 2009 | 6,400 | 200 | 3.23% |
Dec 31, 2008 | 6,200 | 600 | 10.71% |
Dec 31, 2007 | 5,600 | 50 | 0.90% |
Dec 31, 2006 | 5,550 | 150 | 2.78% |
Dec 31, 2005 | 5,400 | 200 | 3.85% |
Dec 31, 2004 | 5,200 | 200 | 4.00% |
Dec 31, 2003 | 5,000 | 0 | - |
Dec 31, 2002 | 5,000 | 189 | 3.93% |
Dec 31, 2001 | 4,811 | -289 | -5.67% |
Dec 31, 2000 | 5,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EW News
- 6 days ago - Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference - Business Wire
- 11 days ago - Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - Business Wire
- 18 days ago - Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Benzinga
- 18 days ago - Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Edwards Lifesciences raises 2025 sales forecast after robust quarter - Reuters
- 19 days ago - Edwards Lifesciences Reports First Quarter Results - Business Wire
- 24 days ago - Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue - Business Wire
- 26 days ago - Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - Business Wire